Approval based on adequate safety data: Bharat Biotech

Bharat Biotech CEO Krishna Ella said he doesn’t know what the regulator meant when it accorded “emergency use permission under clinical trial mode” for the Bharat Biotech vaccine, branded Covaxin. The company is hoping it can run an open trial by vaccinating people as they go without the need for a placebo.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2LmrJw4
via IFTTT